February 28, 2020
Gilead Sciences said on February 26 that it is initiating two PIII clinical trials for its investigational antiviral remdesivir for the treatment of novel coronavirus disease (COVID-19), covering some 1,000 patients mainly across Asian countries. These programs include Japan. The...read more